期刊
MOLECULAR ASPECTS OF MEDICINE
卷 72, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.mam.2019.10.002
关键词
Circulating miRNA; RNA-Seq; RT-qPCR; Cancer; Liquid biopsies
资金
- Czech Science Foundation [P303/18/21942S]
- Standardisation of pre-analytical and analytical procedures for in vitro diagnostics in personalised medicine - SPIDIA4P [EU H2020 SC1-HCO-02-2016]
- IMI call 11 - Blood-based biomarker assays for personalised tumour therapy: value of latest circulating biomarkers [CANCER-ID]
- [RVO 86652036]
- [BIOCEV CZ.1.05/1.1.00/02.0109]
Successful treatment of cancer depends on early diagnosis and effective monitoring of patients' response to therapy. Traditional tools based on tumor biopsies lack the sensitivity and specificity to capture cancer devel-opment in its early phases and are not applicable for continuous monitoring. To overcome these barriers, liquid biopsies have been introduced as a minimally invasive and cost-efficient means of diagnosis with high level of specificity and sensitivity. Traditionally, liquid biopsy markers include circulating tumor cells and circulating tumor DNA. During the last decade, a new promising group of biomarkers has appeared and its utilization for cancer diagnosis and monitoring is intensively studied - the microRNAs (miRNAs). In this review, we provide a comprehensive overview of circulating miRNA analysis. We highlight the importance of sampling and quality control, discuss the technical aspects of miRNA extraction and quantification, summarize recommendations for downstream analysis and conclude with future perspectives. Taken together, we present the current state of knowledge in the field of miRNA analysis in liquid biopsies and the expected development and standardization.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据